Yang Rongli, Liu Chang, Liu Wenli, Luo Jintian, Cheng Shaoli, Mu Xin
Department of Dermatology, First Affiliated Hospital of Xi'an Jiaotong University, No. 277 West Yanta Road, Xi'an, 710061, Shaanxi, China.
Department of Dermatology, Sanzhang Town Health Center, Linwei District, Weinan, Shaanxi, China.
Dermatol Ther (Heidelb). 2022 Oct;12(10):2285-2294. doi: 10.1007/s13555-022-00784-0. Epub 2022 Aug 4.
The persistent erythema and flushing seen in some cases of rosacea do not respond effectively to, or may easily relapse after, oral medication or light-based therapies (laser or intense pulsed light). Intradermal botulinum toxin A (BTX-A) injection can be used to treat intractable erythema and flushing, but studies with large samples and long-term observation have not been conducted to determine its effectiveness and safety. The aim of this study is thus to investigate the effective duration and safety of intradermal BTX-A injection for intractable erythema and flushing.
Sixteen patients with rosacea with erythema telangiectasia were injected with BTX-A at 1-cm intervals between each point. Clinician Erythema Assessment (CEA) scores were obtained at baseline and 1 month after injection. Flushing assessment and survey using the Dermatological Quality of Life Index (DLQI) questionnaire were conducted at baseline and at 1, 3, and 6 months after injection.
At 1 month after injection, CEA scores revealed significant improvements in erythema and flushing; the results of the questionnaire on flushing and DLQI indicated that the improvement of flushing usually lasted for 3-6 months, but the effect decreased significantly at 6 months, and individual patients needed another treatment.
BTX-A significantly improves the symptoms and quality of life of patients with refractory rosacea with few adverse effects.
在某些玫瑰痤疮病例中出现的持续性红斑和潮红，对口服药物或光疗（激光或强脉冲光）反应不佳或容易复发。皮内注射A型肉毒杆菌毒素（BTX-A）可用于治疗顽固性红斑和潮红，但尚未进行大样本和长期观察的研究来确定其有效性和安全性。因此，本研究的目的是探讨皮内注射BTX-A治疗顽固性红斑和潮红的有效持续时间和安全性。
对16例伴有红斑毛细血管扩张的玫瑰痤疮患者，各点之间以1厘米的间隔注射BTX-A。在基线和注射后1个月获得临床医师红斑评估（CEA）评分。在基线以及注射后1、3和6个月使用皮肤病生活质量指数（DLQI）问卷进行潮红评估和调查。
注射后1个月，CEA评分显示红斑和潮红有显著改善；潮红问卷和DLQI的结果表明，潮红的改善通常持续3至6个月，但在6个月时效果显著下降，个别患者需要再次治疗。
BTX-A可显著改善难治性玫瑰痤疮患者的症状和生活质量，且不良反应较少。
